Iqirvo in Bangladesh
How patients in Bangladesh access Iqirvo (resmetirom) via Named Patient Program.
Iqirvo - overview
Iqirvo (resmetirom) is manufactured by Madrigal Pharmaceuticals and indicated for primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA. It is an oral PPARα/δ dual agonist, 80 mg once daily approved by the US FDA in 2024 and may be accessible to patients in Bangladesh through a Named Patient Program or personal-import pathway.
Access in Bangladesh
Bangladesh's DGDA accepts named-patient import under personal-use exceptions; volume is lower but pathway exists.
How Reserve Meds coordinates access in Bangladesh
- Patient or treating physician submits a request.
- We verify clinical appropriateness and Bangladesh-specific eligibility.
- Treating physician in Bangladesh issues prescription and clinical justification.
- Country-specific NPP/personal-import forms are prepared and filed.
- We source Iqirvo from a DSCSA-compliant US specialty wholesaler.
- Cold-chain shipment to the patient's physician or hospital pharmacy in Bangladesh.
Typical timeline for Bangladesh
End-to-end, most requests are completed in 2-6 weeks. Bangladesh's tier 3 regulatory maturity typically supports longer processing times.
What patients and physicians in Bangladesh ask
- Is the pathway legal in Bangladesh? Yes - it operates under Bangladesh's established NPP or personal-import framework.
- Does my insurance cover it? Typically no for NPP drugs; patient prepayment is standard.
- What physician credentials do I need? A licensed physician in Bangladesh able to issue the prescription and clinical justification.
- What if the drug is in shortage? We will inform you upfront and decline rather than promise what we cannot deliver.
- Can I re-supply? Yes - for chronic therapies we arrange ongoing re-supply.